## N.U.P.R.O.

April 9, 1999

Linda S. Kahl, Ph.D.

Office of Special Nutritionals

Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 "C" St. S.W. (HFS-450)

Washington, D.C. 20204

4/3/99

Dear Dr. Kahl:

Nutrition Professionals, Inc. wishes to notify the Food and Drug Administration that it has, within the past 30 days, commenced marketing a dietary supplement which bears a statement under Section(r)(6) of the Federal Food, Drug and Cosmetic Act.

The dietary supplement for which the statement is made is Feverfew Leaf. The dietary ingredient that is the subject of the statement is Feverfew. The statement reads as follows:

"Feverfew helps maintain normal blood vessel tone. Parthenolide also helps normalize the function of platelets in the blood system by inhibiting platelet aggregation, reducing serotonin release from platelets and blocking the formation of pro-inflammatory mediators."

This statement is accompanied by the required disclaimer which is prominently displayed in bold-faced type.

The information contained in this notice is complete and accurate and the above statement is based on data which renders these statements substantiated, truthful and non-misleading.

Sincerely,

NUTRITION PROFESSIONALS, INC.

Gordon M. Walker Regulatory Counsel

lre

THE COMOUNTAIN SPRINGS PARKWAY

pring(引)[284663到JSA

**可能积到的现在** 

Gordon Letter Kahl-NP-Feverfew

975 - 0162

LET 3505